Home > Financial Ratios > BLISS GVS PHARMA

BLISS GVS PHARMA
Core EBITDA Growth

    Back to All Ratios
COMMUNITY POLL
for BLISS GVS PHARMA
Please provide your vote to see the results

BLISS GVS PHARMA Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2024Mar2023Mar2022Mar2021Mar2020
   Core EBITDA Growth(%) 32.75-9.8316.51-20.86-16.78

What is the latest Core EBITDA Growth ratio of BLISS GVS PHARMA ?

The latest Core EBITDA Growth ratio of BLISS GVS PHARMA is 32.75 based on Mar2024 Consolidated results.
Year Core EBITDA Growth
Mar202432.75
Mar2023-9.83
Mar202216.51
Mar2021-20.86
Mar2020-16.78

How is Core EBITDA Growth of BLISS GVS PHARMA Trending?

Years Core EBITDA Growth % Change
Mar2024 32.75
Positive
Mar2023 -9.83
Negative
Mar2022 16.51
Positive
Mar2021 -20.86
Negative
Mar2020 -16.78 -

Other Financial Ratios of BLISS GVS PHARMA


Compare Core EBITDA Growth ratio of peers of BLISS GVS PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
BLISS GVS PHARMA ₹1,266.4 Cr 0.1% -5.1% -0.9% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹405,188.0 Cr -1.5% 4.6% 3% Stock Analytics
DIVIS LABORATORIES ₹143,074.0 Cr -4.8% -3.2% 40.7% Stock Analytics
CIPLA ₹115,768.0 Cr -1.3% -1.9% -5.2% Stock Analytics
TORRENT PHARMACEUTICALS ₹109,809.0 Cr 1.1% 6.1% 27.1% Stock Analytics
DR REDDYS LABORATORIES ₹92,503.5 Cr -3.6% -2.7% -11.4% Stock Analytics


BLISS GVS PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
BLISS GVS PHARMA

0.1%

-5.1%

-0.9%

SENSEX

-2.4%

0.7%

0.5%


You may also like the below Video Courses